SCHEMBL14896977

SCHEMBL14896977

Cc1nc2ccc(N3CC[C@H](N(C)C)C3)nn2c1C(=O)Nc1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 4/20 0.40
▸ MAPK8 P45983 2/20 0.39
▸ BTK Q06187 2/20 0.39
▸ MRGPRX2 Q96LB1 2/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ NTRK3 Q16288 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ MCHR1 Q99705 3/20 0.39
▸ PDE10A Q9Y233 2/20 0.38
▸ GRM5 P41594 1/20 0.38
▸ DGAT2 Q96PD7 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ HTR1D P28221 2/20 0.38
▸ HTR3A P46098 2/20 0.38
▸ HTR6 P50406 2/20 0.38
▸ TMEM97 Q5BJF2 2/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ DRD2 P14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897567 0.90 HRH4 (0.43) AAK1MAPK8BTKMRGPRX2MAPK10
SCHEMBL14897164 0.90 MCHR1 (0.40) AAK1MCHR1PDE10AHRH4HRH3
SCHEMBL16193121 0.89 MCHR1 (0.38) AAK1MAPK8BTKMRGPRX2MAPK10
SCHEMBL14896905 0.89 AAK1 (0.38) AAK1MAPK8BTKMRGPRX2MAPK10
SCHEMBL14897303 0.88 NTRK1 (0.41) NTRK1NTRK3NTRK2GRM5DGAT2
SCHEMBL20356798 0.86 AAK1 (0.39) AAK1MCHR1GRM5HRH4HRH3
SCHEMBL14897434 0.86 AAK1 (0.39) AAK1MCHR1GRM5HRH4HRH3
SCHEMBL14897378 0.84 AAK1 (0.47) AAK1NTRK1NTRK3NTRK2MCHR1
SCHEMBL14897272 0.83 MCHR1 (0.42) AAK1MAPK8BTKMRGPRX2MAPK10
SCHEMBL14897431 0.80 ATR (0.38) AAK1MCHR1HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 AAK1 2011/4885MAPK8 1897/4885BTK 843/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 AAK1 2011/4885MAPK8 1897/4885BTK 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback